Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2024-203488

Published: 2024

Journal Articles

Standard Non-Intensive Chemotherapy Vs Venetoclax-Azacytidine (Ven-AZA) for Unfit AML Patients with Therapy-Related Acute Myeloid Leukaemia (t-AML) - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Lukasz Bolkun, Judyta Strzala, Magdalena Czemerska, Bozena Katarzyna Budziszewska, Aleksandra Golos, Anna Holownia, Wanda Knopinska-Posluszny, Ewa Lech Marańda, Jaroslaw Piszcz, Janusz Halka, Agnieszka Wierzbowska

Blood (2024) 144 (Supplement 1): 6056.

https://doi.org/10.1182/blood-2024-207883

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2024-208144

Published: 2024

Journal Articles

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

Blood (2023) 142 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2023-189713

Published: 2023

Journal Articles

Evaluation of Neddylation and Apoptosis-Related Gene Expression in Patients with Acute Myeloid Leukemia

Kinga Krawiec, Piotr Strzalka, Dariusz Jarych, Aneta Wiśnik, Michał Soin, Magdalena Góralska, Damian Mikulski, Magdalena Czemerska, Izabela Zawlik, Agnieszka Wierzbowska, Agnieszka Pluta

Blood (2023) 142 (Supplement 1): 5990.

https://doi.org/10.1182/blood-2023-181739

Published: 2023

Journal Articles

Assessment of SIRT1-SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia

Piotr Strzalka, Kinga Krawiec, Dariusz Jarych, Aneta Wiśnik, Michał Soin, Magdalena Góralska, Damian Mikulski, Magdalena Czemerska, Izabela Zawlik, Agnieszka Pluta, Agnieszka Wierzbowska

Blood (2023) 142 (Supplement 1): 6048.

https://doi.org/10.1182/blood-2023-187756

Published: 2023

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Kamil Brzozowski, Magdalena Czemerska, Marta Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan M. Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2023) 142 (Supplement 1): 5914.

https://doi.org/10.1182/blood-2023-181633

Published: 2023

Journal Articles

The Signaling Pathways Enriched in High-Risk AML Patients Revealed By the Integrative miRNA-mRNA Analysis - Pilot Study

Magdalena Czemerska, Damian Mikulski, Aneta Wisnik, Dariusz Jarych, Izabela Zawlik, Piotr Strzalka, Kinga Krawiec, Wojciech Fendler, Agnieszka Pluta, Agnieszka Wierzbowska

Blood (2023) 142 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2023-174968

Published: 2023

Journal Articles

Proteomic Landscape of Circulating Exosomes during Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients

Damian Mikulski, Izabela Dróżdż, Mateusz Nowicki, Małgorzata Misiewicz, Grzegorz Mirocha, Ewelina Perdas, Agnieszka Wierzbowska, Wojciech Fendler

Blood (2023) 142 (Supplement 1): 6614.

https://doi.org/10.1182/blood-2023-190171

Published: 2023

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Marta Anna Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2022) 140 (Supplement 1): 6165–6166.

https://doi.org/10.1182/blood-2022-163109

Published: 2022

Journal Articles

The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients

Magdalena Czemerska, Aneta Wisnik, Dariusz Jarych, Izabela Zawlik, Piotr Strzałka, Kinga Krawiec, Barbara Cebula-Obrzut, Agata Majchrzak, Kamil Brzozowski, Marcin Kozlowski, Agnieszka Pluta, Agnieszka Wierzbowska

Blood (2022) 140 (Supplement 1): 6252–6253.

https://doi.org/10.1182/blood-2022-156736

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 11836–11837.

https://doi.org/10.1182/blood-2022-170126

Published: 2022

Journal Articles

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 3206–3207.

https://doi.org/10.1182/blood-2022-166227

Published: 2022

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Blood (2022) 140 (12): 1345–1377.

https://doi.org/10.1182/blood.2022016867

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Standard Non-Intensive Chemotherapy Vs Venetoclax-Azacytidine (Ven-AZA) for Unfit AML Patients with Therapy-Related Acute Myeloid Leukaemia (t-AML) - a Retrospective Study of Polish Adult Leukemia Group (PALG)

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

Evaluation of Neddylation and Apoptosis-Related Gene Expression in Patients with Acute Myeloid Leukemia

Assessment of SIRT1-SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

The Signaling Pathways Enriched in High-Risk AML Patients Revealed By the Integrative miRNA-mRNA Analysis - Pilot Study

Proteomic Landscape of Circulating Exosomes during Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only